Zacks Industry Outlook Highlights Veracyte, IDEXX Laboratories and Intuitive Surgical

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• IDEXX Laboratories holds a Zacks Rank #2 (Buy)

  80% confidence

• The application of AI in the diagnostics space is growing enormously, with the market expected to witness a CAGR of 20.4% by 2034

  80% confidence

• Intuitive Surgical's 2025 EPS consensus estimate is $8.65, representing 17.9% growth year-over-year

  80% confidence

• The top 50% of Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1

  80% confidence

• The Medical Instruments industry's five-year P/E range has been as high as 40.76X, as low as 25.73X, with a median of 32.28X

  80% confidence

• The Zacks Medical Instruments industry is trading at a forward 12-month P/E of 30.36X, compared with the broader industry's 21.29X and the S&P 500's 23.42X

  80% confidence

• Overall MedTech M&A activity remained below historical norms, with only 46 announced deals through November 30, 2025

  80% confidence

• Intuitive Surgical's 2025 sales consensus estimate is $9.92 billion, representing 18.7% growth from 2024

  80% confidence

• Global generative AI in the healthcare market is valued at $2.64 billion in 2025 and is expected to witness a CAGR of 35.2% through 2034

  80% confidence

• The Zacks Medical Instruments industry carries a Zacks Industry Rank #161, placing it in the bottom 33% of 243 Zacks industries

  80% confidence

• Intuitive Surgical holds a Zacks Rank #2 (Buy)

  80% confidence

• Veracyte's 2025 sales consensus estimate is $508.6 million, representing 14.1% growth from 2024

  80% confidence

• Global growth is expected to remain at 3.2% in 2025 and 3.1% in 2026, below the pre-pandemic average of 3.7%

  80% confidence

• Veracyte's 2025 EPS consensus estimate is $1.65, representing 38.7% growth from 2024

  80% confidence

• Zacks top stock-picking strategies have averaged gains of +48.4%, +50.2%, and +56.7% per year since 2000, versus the S&P's +7.7% average annual gain

  80% confidence

• Veracyte holds a Zacks Rank #1 (Strong Buy)

  80% confidence

• IDEXX Laboratories' 2025 sales consensus estimate is $4.28 billion, representing 9.9% growth

  80% confidence

• IDEXX Laboratories' 2025 EPS consensus estimate is $12.93, representing 21.2% growth

  80% confidence

• MedTech deal value surged to $92.8 billion in 2025, the highest level in more than a decade, driven by three mega-deals

  80% confidence

• Global headline inflation is expected to decline to 4.2% in 2025 and to 3.7% in 2026

  80% confidence

• Global AI in the healthcare market is projected to witness a CAGR of 44% from 2025 to 2032

  80% confidence